Device Trial Radar · NCT05746286
Remote Monitoring of Vital Signs With Telehealth to Prevent Readmissions for Dysglycemia
Last checked: Nov 19, 2026Latest source record: Nov 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Feb 1, 2023
Primary completion
Nov 29, 2023
Study completion Jun 24, 2024
Sponsor
- Lead sponsor
- DexCom, Inc.Public (DXCM)
- Sponsor type
- Industry
- First posted
- Feb 27, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 21 years, up to 110 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients who have experienced dysglycemia in hospital (either from diabetes, post-solid organ transplantation, medication titration, or other causes) may struggle to manage their blood glucose when discharged home. This may lead to ER visits or readmissions that could have been prevented if glucose variations were detected before reaching extremes, and the variations were contextualized with other vital sign parameters. Remote monitoring via Dexcom G6 and Current Health (vital signs) used concomitantly after discharged for the purpose of remote monitoring will be evaluated with respect to ER visits and readmissions while considering the impact and usability of the potential integrated system on the healthcare staff.
Conditions
- Dysglycemia
Interventions
Dexcom G6 CGMDevice
Once discharged, the patients will be monitored by the endocrine team via routine "dashboard rounds" during working hours (8AM-5PM). Outside of dashboard rounds, management will be by exception, based on platform alarms directed to the endocrinology service.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduce amount of ER readmission in first 30 days after dischargeTime frame: 30 days
- Pilot study satisfaction surveyTime frame: 30 days or less per patient
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mount Sinai School of Medicine
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.